Denis Tvorogov

South Australia Pathology — Australia

Medicine · Health Sciences

23h-index2.4kcitations150works0.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Chronic Myeloid Leukemia Treatments(39), Cytokine Signaling Pathways and Interactions(37), CAR-T cell therapy research(34), Myeloproliferative Neoplasms: Diagnosis and Treatment(31), Acute Myeloid Leukemia Research(23)

Publications150 total

Ultraprecision Therapy for Type 1 vs Type 2 CALR+ MPN by Dual Epitope Targeting that Restores Ruxolitinib Sensitivity
Blood·2026
Supplementary Table S2 from Distinct Assemblies of Heterodimeric Cytokine Receptors Govern Stemness Programs in Leukemia
2025Open Access
Figure S5 from Distinct Assemblies of Heterodimeric Cytokine Receptors Govern Stemness Programs in Leukemia
2025Open Access
Figure S4 from Distinct Assemblies of Heterodimeric Cytokine Receptors Govern Stemness Programs in Leukemia
2025Open Access
Figure S7 from Distinct Assemblies of Heterodimeric Cytokine Receptors Govern Stemness Programs in Leukemia
2025Open Access
Figure S1 from Distinct Assemblies of Heterodimeric Cytokine Receptors Govern Stemness Programs in Leukemia
2025Open Access
Figure S3 from Distinct Assemblies of Heterodimeric Cytokine Receptors Govern Stemness Programs in Leukemia
2025Open Access
Figure S6 from Distinct Assemblies of Heterodimeric Cytokine Receptors Govern Stemness Programs in Leukemia
2025Open Access
Figure S2 from Distinct Assemblies of Heterodimeric Cytokine Receptors Govern Stemness Programs in Leukemia
2025Open Access
Supplementary Table S1 from Distinct Assemblies of Heterodimeric Cytokine Receptors Govern Stemness Programs in Leukemia
2025Open Access
Supplementary Methods from Next-Generation JAK2 Inhibitors for the Treatment of Myeloproliferative Neoplasms: Lessons from Structure-Based Drug Discovery Approaches
2025Open Access
Supplementary Figure S1 from Next-Generation JAK2 Inhibitors for the Treatment of Myeloproliferative Neoplasms: Lessons from Structure-Based Drug Discovery Approaches
2025Open Access
Supplementary File 2 from Next-Generation JAK2 Inhibitors for the Treatment of Myeloproliferative Neoplasms: Lessons from Structure-Based Drug Discovery Approaches
2025Open Access
Supplementary Movie from Next-Generation JAK2 Inhibitors for the Treatment of Myeloproliferative Neoplasms: Lessons from Structure-Based Drug Discovery Approaches
2025Open Access
TGF-β regulates CD123 and chemotherapy resistance in Acute Myeloid Leukemia stem cells
Blood·2025
2014 – TGFΒ1 REGULATES LEUKEMIA STEM CELL MARKER CD123 AND INDUCES CHEMOTHERAPY RESISTANCE
Experimental Hematology·2025
The β Common Cytokine Receptor Family Reveals New Functional Paradigms From Structural Complexities
Immunological Reviews·2025· 5 citedOpen Access
Defective kinase activity of IKKα leads to combined immunodeficiency and disruption of immune tolerance in humans
Nature Communications·2024· 2 citedOpen Access
Transforming Growth Factor Beta 1/SMAD2 Signalling Axis Regulates Leukemia Stem Cell Marker CD123: Implications for Acute Myeloid Leukemia
Blood·2024· 1 cited
Supplementary Table S2 from Distinct assemblies of heterodimeric cytokine receptors govern stemness programs in leukemia
2024Open Access
page 1 of 8Next →

Frequent Co-authors

Angel F. López(28), Danièl Thomas(20), Winnie L. Kan(17), Timothy R. Hercus(16), Michael W. Parker(16), Tracy L. Nero(14), Mara Dottore(13), Kari Alitalo(12), Karen S. Cheung Tung Shing(12), Sophie E. Broughton(11), Urmi Dhagat(11), Emma F. Barry(11), David M. Ross(11), Paul G. Ekert(10), Kerstin B. Kaufmann(9), Andy G.X. Zeng(9), John Toubia(9), Guillermo A. Gómez(9), Brooks A. Benard(9), Héléna Boutzen(9)